Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes (PROMPT)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Saxagliptin
Metformin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Type 2 Diabetes Mellitus, Saxagliptin, Randomised, Double-blind
Eligibility Criteria
Inclusion Criteria:
- Provision of signed informed consent
- Established clinical diagnosis of type 2 diabetes. Treatment with a stable dose of metformin monotherapy (1500-1700 mg/day) for at least 8 weeks prior to visit 1.
- HbA1c ≥7.0% and ≤10.0%
Exclusion Criteria:
- Type 1 diabetes, history of diabetic ketoacidosis or hyperosmolar non-ketonic coma.
- Renal impairment as defined by a creatinine clearance <60 mL/min/1.73 m2
- Individuals who, in the opinion of the investigator, in which participation in this study may pose a significant risk to the patient and could render the patient unable to successfully complete the study
Sites / Locations
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
1
2
Arm Description
Saxagliptin 5 mg
Metformin 500 -1000 mg
Outcomes
Primary Outcome Measures
Absolute Change From Baseline in HbA1c at Week 24
Secondary Outcome Measures
Proportion of Patients Achieving a Therapeutic Response at Week 24 Defined as HbA1c<7.0%
Proportion, percentage of patients in each treatment group, achieving therapeutic response, HbA1c below 7.0 percent
Proportion of Patients Achieving a Therapeutic Response at Week 24 Defined as HbA1c<=6.5%
Proportion, percentage of patients in each treatment group, achieving therapeutic response, HbA1c below or equal to 6.5 percent
Change From Baseline to Week 24 in Fasting Plasma Glucose
Change From Baseline to Week 24 in Fasting Insulin
Change From Baseline to Week 24 in Beta-cell Function as Measured by Homeostasis Model Assessment-2-beta
Full Information
NCT ID
NCT01006590
First Posted
October 31, 2009
Last Updated
January 16, 2012
Sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb
1. Study Identification
Unique Protocol Identification Number
NCT01006590
Brief Title
Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes
Acronym
PROMPT
Official Title
A 24-Week, Randomised, Double-Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Add-On Compared to Uptitration of Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Sub-Maximal Doses of Metformin
Study Type
Interventional
2. Study Status
Record Verification Date
January 2012
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
Collaborators
Bristol-Myers Squibb
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study will evaluate the efficacy and tolerability of saxagliptin compared to uptitration of metformin in patients with type 2 diabetes who have inadequate glycaemic control on a submaximal dose of metformin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Type 2 Diabetes Mellitus, Saxagliptin, Randomised, Double-blind
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
286 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Saxagliptin 5 mg
Arm Title
2
Arm Type
Active Comparator
Arm Description
Metformin 500 -1000 mg
Intervention Type
Drug
Intervention Name(s)
Saxagliptin
Other Intervention Name(s)
Onglyza
Intervention Description
5 mg, oral tablet, once daily
Intervention Type
Drug
Intervention Name(s)
Metformin
Intervention Description
500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy
Primary Outcome Measure Information:
Title
Absolute Change From Baseline in HbA1c at Week 24
Time Frame
Baseline and 24 weeks
Secondary Outcome Measure Information:
Title
Proportion of Patients Achieving a Therapeutic Response at Week 24 Defined as HbA1c<7.0%
Description
Proportion, percentage of patients in each treatment group, achieving therapeutic response, HbA1c below 7.0 percent
Time Frame
24 Weeks
Title
Proportion of Patients Achieving a Therapeutic Response at Week 24 Defined as HbA1c<=6.5%
Description
Proportion, percentage of patients in each treatment group, achieving therapeutic response, HbA1c below or equal to 6.5 percent
Time Frame
24 Weeks
Title
Change From Baseline to Week 24 in Fasting Plasma Glucose
Time Frame
Baseline and 24 weeks
Title
Change From Baseline to Week 24 in Fasting Insulin
Time Frame
Baseline and 24 weeks
Title
Change From Baseline to Week 24 in Beta-cell Function as Measured by Homeostasis Model Assessment-2-beta
Time Frame
Baseline and 24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Provision of signed informed consent
Established clinical diagnosis of type 2 diabetes. Treatment with a stable dose of metformin monotherapy (1500-1700 mg/day) for at least 8 weeks prior to visit 1.
HbA1c ≥7.0% and ≤10.0%
Exclusion Criteria:
Type 1 diabetes, history of diabetic ketoacidosis or hyperosmolar non-ketonic coma.
Renal impairment as defined by a creatinine clearance <60 mL/min/1.73 m2
Individuals who, in the opinion of the investigator, in which participation in this study may pose a significant risk to the patient and could render the patient unable to successfully complete the study
Facility Information:
Facility Name
Research Site
City
Brugge
Country
Belgium
Facility Name
Research Site
City
Brussels (woluwe-st-lambert)
Country
Belgium
Facility Name
Research Site
City
Halen
Country
Belgium
Facility Name
Research Site
City
Lommel
Country
Belgium
Facility Name
Research Site
City
Moerkerke
Country
Belgium
Facility Name
Research Site
City
Oostham
Country
Belgium
Facility Name
Research Site
City
Sint-gillis-waas
Country
Belgium
Facility Name
Research Site
City
Tielt
Country
Belgium
Facility Name
Research Site
City
Zoersel
Country
Belgium
Facility Name
Research Site
City
Chatellerault
Country
France
Facility Name
Research Site
City
Corbeil Essonnes
Country
France
Facility Name
Research Site
City
La Rochelle
Country
France
Facility Name
Research Site
City
La Seyne Sur Mer
Country
France
Facility Name
Research Site
City
Paris
Country
France
Facility Name
Research Site
City
Seysses
Country
France
Facility Name
Research Site
City
Tierce
Country
France
Facility Name
Research Site
City
Berlin
Country
Germany
Facility Name
Research Site
City
Freiburg
Country
Germany
Facility Name
Research Site
City
Leipzig
Country
Germany
Facility Name
Research Site
City
Ludwigshafen
Country
Germany
Facility Name
Research Site
City
Mannheim
Country
Germany
Facility Name
Research Site
City
Rhaunen
Country
Germany
Facility Name
Research Site
City
Schmiedeberg
Country
Germany
Facility Name
Research Site
City
Wahlstedt
Country
Germany
Facility Name
Research Site
City
Bergamo
State/Province
BG
Country
Italy
Facility Name
Research Site
City
Forli
State/Province
FC
Country
Italy
Facility Name
Research Site
City
Milano
State/Province
MI
Country
Italy
Facility Name
Research Site
City
Padova
State/Province
PD
Country
Italy
Facility Name
Research Site
City
Pordenone
State/Province
PN
Country
Italy
Facility Name
Research Site
City
Siena
State/Province
SI
Country
Italy
Facility Name
Research Site
City
Roma
Country
Italy
Facility Name
Research Site
City
Sevilla
State/Province
Andalucia
Country
Spain
Facility Name
Research Site
City
Oviedo
State/Province
Asturias
Country
Spain
Facility Name
Research Site
City
Barcelona
State/Province
Cataluna
Country
Spain
Facility Name
Research Site
City
Madrid
State/Province
Comunidad de Madrid
Country
Spain
Facility Name
Research Site
City
San Sebastian de Los Reyes
State/Province
Comunidad de Madrid
Country
Spain
Facility Name
Research Site
City
Alicante
State/Province
Comunidad Valenciana
Country
Spain
Facility Name
Research Site
City
A Coruna
State/Province
Galicia
Country
Spain
Facility Name
Research Site
City
Ankara
Country
Turkey
Facility Name
Research Site
City
Bursa
Country
Turkey
Facility Name
Research Site
City
Kirikkale
Country
Turkey
Facility Name
Research Site
City
Reading
State/Province
Berks
Country
United Kingdom
Facility Name
Research Site
City
Atherstone
State/Province
Warwickshire
Country
United Kingdom
Facility Name
Research Site
City
Leamington Spa
State/Province
Warwks
Country
United Kingdom
Facility Name
Research Site
City
Warminster
State/Province
Wiltshire
Country
United Kingdom
Facility Name
Research Site
City
Westbury
State/Province
Wiltshire
Country
United Kingdom
Facility Name
Research Site
City
Ashford
Country
United Kingdom
Facility Name
Research Site
City
Bath
Country
United Kingdom
Facility Name
Research Site
City
Coventry
Country
United Kingdom
Facility Name
Research Site
City
Peterborough
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
23020253
Citation
Hermans MP, Delibasi T, Farmer I, Lohm L, Maheux P, Piatti P, Malvolti E, Jorgens S, Charbonnel B. Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. Curr Med Res Opin. 2012 Oct;28(10):1635-45. doi: 10.1185/03007995.2012.735646. Epub 2012 Oct 12.
Results Reference
derived
Learn more about this trial
Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes
We'll reach out to this number within 24 hrs